GNPX
Genprex, Inc. NASDAQ Listed Mar 29, 2018$0.59
+22.47%
vs $0.48
Mkt Cap $552,176
52w Low $0.44
0.4% of range
52w High $42.00
50d MA $0.87
200d MA $4.05
P/E (TTM)
-0.0x
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-203.8%
P/FCF
-0.0x
RSI (14)
33.90
ATR (14)
$0.06
Beta
-0.67
50d MA
$0.87
200d MA
$4.05
Avg Volume
358.4K
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
3300 Bee Cave Road · Austin, TX 78746 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -13.00 | -1.15 | +91.2% | 1.77 | -2.3% | +2.3% | -12.7% | -2.5% | -5.8% | -5.5% | — |
| Nov 14, 2025 | AMC | -12.50 | -5.00 | +60.0% | 4.43 | +0.0% | -8.8% | -8.7% | -9.5% | -5.4% | -5.1% | — |
| Aug 14, 2025 | AMC | -21.00 | -8.50 | +59.5% | 10.80 | +0.1% | -1.8% | -10.0% | -10.9% | -4.2% | -11.8% | — |
| May 12, 2025 | AMC | -0.82 | -0.26 | +68.3% | 13.80 | +1.5% | +2.2% | -20.9% | +6.2% | +4.4% | +9.2% | — |
| Apr 7, 2025 | AMC | -0.82 | -1.15 | -40.2% | 15.51 | +4.8% | -17.9% | +8.0% | -3.6% | +0.6% | -0.8% | — |
| Nov 13, 2024 | AMC | -1.13 | -1.23 | -8.8% | 80.00 | +2.5% | +2.5% | -2.4% | -15.0% | -5.1% | -14.7% | — |
| Aug 9, 2024 | AMC | -2.30 | -3.00 | -30.4% | 71.00 | +4.9% | -11.3% | -32.5% | -14.1% | -10.7% | -0.6% | — |
| May 15, 2024 | AMC | -2.54 | -3.69 | -45.3% | 125.50 | -1.2% | -3.6% | +5.4% | -4.3% | -3.7% | +0.9% | — |
| Mar 29, 2024 | AMC | -3.93 | -3.96 | -0.8% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -0.11 | -5.20 | -4627.3% | 470.00 | +1.5% | +10.6% | -8.4% | +3.9% | +4.8% | -0.7% | — |
| Aug 21, 2023 | AMC | -4.80 | -6.00 | -25.0% | 898.50 | -2.6% | +7.8% | -5.2% | -0.3% | +1.6% | +0.4% | — |
| May 22, 2023 | AMC | -4.80 | -7.60 | -58.3% | 1575.00 | -0.3% | -0.2% | -0.8% | +9.0% | +4.7% | -9.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $121.00 | $124.50 | +2.9% | +5.4% | -4.3% | -3.7% | +0.9% | -6.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $128.50 | $127.00 | -1.2% | -2.3% | -3.6% | +5.4% | -4.3% | -3.7% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $155.50 | $157.50 | +1.3% | -3.9% | +0.3% | -1.3% | +3.7% | -6.2% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $142.00 | $144.50 | +1.8% | +9.5% | -3.9% | +0.3% | -1.3% | +3.7% |
No insider trades available.
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex's lead lung cancer gene therapy candidate Reqorsa showed positive biomarker data at ASCO 2026, potentially validating its clinical approach and supporting future trial progression.
May 26
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex's collaborators presented preclinical data showing its GPX-002 diabetes gene therapy reversed hyperglycemia in Type 2 diabetic mouse models, potentially validating a novel therapeutic approach.
May 14
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex secured an Israeli patent for its Reqorsa gene therapy combined with PD-1 antibodies in cancer treatment, strengthening its intellectual property portfolio and competitive position in immunotherapy.
Apr 30
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex's diabetes gene therapy candidate GPX-002 will present positive preclinical data at the 2026 ASGCT conference, potentially validating its therapeutic approach and supporting future clinical development.
Apr 28
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex partnered with UT MD Anderson to conduct biomarker research on its lead lung cancer gene therapy candidate Reqorsa, potentially enabling patient stratification for future clinical trials.
Apr 21
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
GNPX's TUSC2 therapeutic candidate shows concerning 50% resistance rate in lung cancer cell lines, potentially limiting its market addressable population and clinical viability.
Mar 18
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex secured patent protection in Japan and Europe for Reqorsa combination therapies with checkpoint inhibitors, strengthening its intellectual property position and potential commercial exclusivity for cancer treatments.
Feb 23
8-K · 8.01
!! High
Genprex, Inc. -- 8-K 8.01: Material Event / Announcement
Genprex received Australian patent acceptance for its Reqorsa gene therapy combined with PD-L1 antibodies for cancer treatment, strengthening its intellectual property protection across multiple jurisdictions.
Feb 10
Institutional (13F) — Top 13
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Mayflower Financial Advisors, Llc | 20,000 | $36K | New | Mar 2026 |
| 2 | Manchester Financial Inc | 20,000 | $36K | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 5,950 | $11K | New | Mar 2026 |
| 4 | Fny Investment Advisers, Llc | 5,000 | $9K | New | Mar 2026 |
| 5 | Cygnus Capital Advisors, Llc | 2,195 | $4K | New | Mar 2026 |
| 6 | Morgan Stanley | 12 | $22 | New | Dec 2025 |
| 7 | Highmark Wealth Management Llc | 10 | $18 | — | Mar 2026 |
| 8 | Citigroup Inc | 4 | $7 | New | Dec 2025 |
| 9 | Jpmorgan Chase & Co | 2 | $4 | — | Mar 2026 |
| 10 | Ubs Group Ag | 1 | $2 | Reduced | Mar 2026 |
| 11 | Danske Bank A/s | 1 | $2 | — | Mar 2026 |
| 12 | Curio Wealth, Llc | 1 | $2 | — | Mar 2026 |
| 13 | Capital Advisors, Ltd. Llc | 1 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 14,005 | $28K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 1,522 | $3K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 685 | $1K | Feb 2026 |
Valuation
Market Cap
$552K
Enterprise Value
-$7.3M
P/E (TTM)
-0.03x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.07x
P/S
—
P/FCF
-0.04x
EV/EBITDA
—
Shares Out
933K
Financials (TTM)
Revenue
$0
Net Income
-$16.2M
EBITDA
-$15.5M
Free Cash Flow
-$15.3M
Op Cash Flow
-$15.3M
EPS Basic
$-17.40
EPS Diluted
$-17.40
EPS Forward
$-57.50
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$10.2M
Total Liab.
$2.2M
Total Equity
$8.0M
Cash
$7.8M
LT Debt
$0
Book Value/Sh
$8.54
Debt/Equity
0.00x
Current Ratio
3.84
Quick Ratio
3.84
Returns & Growth
ROE
-203.8%
ROA
-159.8%
ROIC
-194.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+93.5%
Price Returns
2W
-9.5%
1M
-20.1%
3M
-61.0%
6M
-73.7%
12M
-95.3%
Technicals
52W High
$42.00
52W Low
$0.44
50d MA
$0.87
200d MA
$4.05
RSI (14)
33.90
ATR (14)
$0.06
Beta
-0.67
Avg Volume
358K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 11:52am
· Source: financialmodelingprep.com